Medicamen Biotech Q1FY27: consolidated PAT +15% YoY, margin dips on cost spike

Medicamen Biotech's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 11.3% YoY to ₹47.90 Cr from ₹43.04 Cr, with consolidated PAT up 15.3% YoY to ₹1.85 Cr from ₹1.60 Cr and EPS at ₹1.36 versus ₹1.18. Sequentially both lines fell sharply — revenue down 21.0% and PAT down 58.5% — off a stronger ₹60.65 Cr / ₹4.45 Cr March quarter. Management gives no formal guidance or outlook on record for this print to be checked against, and no analyst coverage or consensus estimates were found for the stock, so there is no street benchmark either; no management press release was available to cross-check against the reported numbers. Operating margin compressed to 9.03% from 10.72% a year ago, even though it was roughly flat sequentially (8.97% in Q4 FY26). The squeeze traces to other expenses, which rose 72.3% YoY to ₹13.14 Cr (from ₹7.63 Cr) on the consolidated base — outpacing the 11.3% revenue growth — while cost of material consumed actually improved as a share of revenue, falling to 47.2% from 57.1% a year earlier. Net margin held roughly steady at 3.79% versus 3.68% YoY (down sharply from 7.13% in Q4 FY26), as the lower material-cost ratio partly offset the other-expense drag. Standalone PAT of ₹2.53 Cr grew a much faster 54.4% YoY (from ₹1.64 Cr) — the gap versus consolidated growth of 15.3% is explained by a combined ₹0.69 Cr net loss at subsidiaries Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited on ₹4.04 Cr of subsidiary revenue this quarter, per the auditors' review report; the group (consolidated) figure is the weaker of the two bases. No exceptional items appear in either period, and both statements carry unmodified limited-review opinions. Separately, the board this quarter noted BSE and NSE fines of ₹1.11 lakh each for a Nomination & Remuneration Committee composition lapse (Regulation 19(1)/19(2)), already remitted on June 2, 2026 — a governance footnote with no bearing on the P&L.